topic 1. validation of procedures to prevent contamination and cross-contamination with tse agents...
TRANSCRIPT
![Page 1: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/1.jpg)
Topic 1. Validation of Procedures to Prevent Contamination and
Cross-Contamination with TSE Agents of Human Tissue
Intended for Transplantation
TSEAC June 26, 2002
![Page 2: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/2.jpg)
Issue
• FDA requests advice from TSEAC on– Measures for donor screening– Measures for tissue recovery and processing– Clearance of TSE agents (design of a study)
– Appropriate to prevent contamination and cross-contamination of human cells, tissues, and cellular and tissue-based products (HCT/Ps) by TSE agents
![Page 3: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/3.jpg)
Background
• Three approaches to reduce risk of TSE transmission:– (1) careful screening of donor for TSE and
risk factors of TSE (testing if and when validated)
– (2) control of recovery and processing to prevent contamination/cross-contamination
– (3) use of steps during manufacturing to remove or inactivate (clear) TSE agents
![Page 4: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/4.jpg)
Iatrogenic transmission through HCT/Ps
• Human dura mater transplantation– >100 cases worldwide (3 in U.S.)– Most from dura mater that had been commingled
during processing
• Human corneal transplantation– 1 definite case (U.S., 1974)– 1 probable case (Japan, 1994)– 1 possible case (Germany, 1997)– Potential cases (U.K., 1999)
• Human pituitary-derived hormone administration—to be discussed
![Page 5: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/5.jpg)
Potential Transmission of CJD/vCJD by Other HCT/Ps
• Experimental evidence in animals– Brown P et al. Annals of Neurology 1994—
300 cases of experimentally transmitted human spongiform encephalopathies
![Page 6: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/6.jpg)
FDA’s Regulatory Approach to TSE Transmission (actual and
potential) by HCT/Ps
• Current regulations (rules)
• Current recommendations (guidance)
• Proposed regulations
• Proposed recommendations
![Page 7: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/7.jpg)
Current Regulations
• 21 CFR part 1270—Human Tissue Intended for Transplantation--1997– Screening and testing of potential donors for HIV,
HBV, HCV (TSE not included); written procedures; records
– Validated procedures to prevent infectious disease contamination or cross-contamination by tissue during processing-1270.31(d)
– Inspection and enforcement provisions
![Page 8: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/8.jpg)
Current Recommendations
• (1) Guidance for Industry: Screening and Testing of Donors of Human Tissue Intended for Transplantation (’97)--defer donors with:– Diagnosis of CJD– Family history of CJD– History of receiving dura mater transplant– History of receiving human pituitary growth
hormone
![Page 9: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/9.jpg)
Current Recommendations, cont.
• (2) Guidance for Industry: Validation of Procedures for Processing of Human Tissues Intended for Transplantation (3/’02)—clarifies 1270.31– Infectious disease contamination includes viral,
bacterial, fungal and TSE agents– Validated methods to prevent contamination by
viruses, bacteria, fungi now– Validated methods to prevent contamination by
TSE agents—if and when such methods are agreed upon by scientific experts; become available
![Page 10: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/10.jpg)
Current Recommendations, cont.
• (3) Guidance for the Preparation of a Premarket Notification Application for Processed Human Dura Mater (10/’99)– All of above donor suitability recommendations; any
degenerative or demyelinating disease of CNS; death in a neurological/psychiatric hospital
– Gross and histological exam of full brain– Disinfection by a method validated to reduce CJD
infectivity– Prohibition of batch processing
![Page 11: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/11.jpg)
Proposed Regulations
• (1) Suitability Determination for Donors of Human Cellular and Tissue-Based Products; Proposed Rule (9/30/99)– Screening (including medical history
interview) for risk factors and clinical evidence of HIV, HBV, HCV, TSEs; additional screening for particular HCT/Ps
– Testing for HIV, HBV, HCV, syphilis; additional testing for particular HCT/Ps
![Page 12: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/12.jpg)
Proposed Regulations, cont.
• (2) Current Good Tissue Practice for Manufacturers of HCT/Ps; Inspection and Enforcement; Proposed Rule (1/8/01)– Controls over facilities, personnel, equipment,
environment, incoming materials, labeling, storage, process controls, process validation, record keeping, adverse reaction and product deviation reporting, tracking
– Inspection and enforcement
![Page 13: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/13.jpg)
Proposed Regulations, cont.
• (2) GTP – Prohibition of pooling (placing in physical contact
or mixed in a single receptacle)
– Exemption or alternative from any GTP requirement—submit request with valid data• Ex.-request for an exemption from pooling prohibition:
FDA would weigh potential increased risk of contamination and cross-contamination with emerging infectious disease agents (e.g., TSE agents) against potential benefit of improved elimination of conventional infectious disease agents (virus, bacteria, fungi)
![Page 14: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/14.jpg)
Proposed Recommendations
• Draft guidance for comment about donor screening and deferral to reduce possible risk of CJD/vCJD transmission by HCT/Ps—risk factors for CJD and vCJD--deferrals for travel/residence in BSE-affected countries—similar to guidance for blood donors (1/’02)
![Page 15: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/15.jpg)
Additional Donor Screening Measures
• (1) Upper age limit for donors– Median age at death from CJD is 68 years – ?incubation period--?infectious during incubation
period– Proposed for blood donors, but not implemented– May seriously reduce tissue supply (e.g., 50% of U.S.
donors of ocular tissue are age 61 or older)– Not recommended by tissue bank or eye bank
standards, except semen donors <40; oocyte donors <35; donors of cardiovascular tissue <61; at the discretion of individual medical director
![Page 16: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/16.jpg)
Additional Donor Screening Measures, cont.
• (2) Exclusion for head trauma– To avoid possible CNS contamination– Not addressed in industry standards– May reduce tissue supply (e.g., 13% of eye
donors’ cause of death is trauma)
![Page 17: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/17.jpg)
Additional Donor Screening Measures, cont.
• (3) Negative brain autopsy– Delay in distributing time-sensitive HCT/Ps
(e.g., cornea)
• (4) Negative brain biopsy– Would need to be validated to show that is it
predictive of autopsy diagnosis of TSE
![Page 18: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/18.jpg)
Charge
• Evaluate appropriateness of the measures and controls discussed (or other) to prevent TSE transmission to recipients of HCT/Ps– Additional donor screening criteria– Specified methods of recovery and processing
specific methods of decontaminationremoval and/or inactivation of TSE
agents
![Page 19: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/19.jpg)
Charge, cont.
• Should pooling (commingling) of HCT/Ps from different donors during manufacturing ever be permitted? If so, what controls should FDA require in assessing whether a request for an exemption from the proposed pooling prohibition should be granted?
![Page 20: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/20.jpg)
Questions for the Committee
• 1. Which of the following measures and controls is (are) appropriate to prevent TSE agent transmission to recipients of human cells and tissues?
![Page 21: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/21.jpg)
Questions, cont.
– 1. A. Recommend additional donor eligibility/exclusion criteria• Upper age limit• Head trauma exclusion• Negative brain autopsy or biopsy
![Page 22: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/22.jpg)
Questions, cont.
– 1. B. Recommend specified methods of HCT/P recovery and/or processing to prevent contamination and cross-contamination by TSE agents• Decontamination of instruments and surfaces• Methods for removal and/or inactivation of TSE
agents during manufacturing• Single donor aseptic processing or permit pooled
processing under certain circumstances (which ones?) with adequate controls (which ones?)
![Page 23: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/23.jpg)
Questions, cont.
• 1. C. Other appropriate measures and controls
![Page 24: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/24.jpg)
Questions, cont.
• 2. Please comment on the design of a satisfactory TSE agent clearance study for HCT/Ps, in terms of the following criteria:– A. Suitable TSE agent strain and animal
model– B. Accept measurement of abnormal forms
of prion protein alone, or require infectivity assays
![Page 25: Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649dcf5503460f94ac4485/html5/thumbnails/25.jpg)
Questions, cont.
• 2. Design of a clearance study, cont.– C. Accept substantial reduction (how
much?) or require complete elimination of detectable prion protein and/or infectivity
– D. Accept a single validated method or require that more than one validated method for eliminating TSE agents be included in the study
– E. Other